These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36427340)

  • 21. Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States.
    Fonseca AF; Byrne H; Laguna A; Itani T; Studer R; Heo J; Dillon A; Ferber P; Costa-Scharplatz M
    J Manag Care Spec Pharm; 2023 May; 29(5):519-529. PubMed ID: 37121256
    [No Abstract]   [Full Text] [Related]  

  • 22. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
    Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
    J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.
    Reynaud Q; Durieu I; Dutertre M; Ledochowski S; Durupt S; Michallet AS; Vital-Durand D; Lega JC
    Autoimmun Rev; 2015 Apr; 14(4):304-13. PubMed ID: 25497766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
    Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
    [No Abstract]   [Full Text] [Related]  

  • 25. Healthcare costs and resource utilization in patients with severe aplastic anemia in the US.
    Cai B; Said Q; Li X; Li FY; Arcona S
    J Med Econ; 2019 Oct; 22(10):1055-1062. PubMed ID: 31296074
    [No Abstract]   [Full Text] [Related]  

  • 26. The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma-based severity levels: Insights from a large US commercial and managed Medicaid population.
    Pollack M; Gandhi H; Tkacz J; Lanz M; Lugogo N; Gilbert I
    J Manag Care Spec Pharm; 2022 Aug; 28(8):881-891. PubMed ID: 35708342
    [No Abstract]   [Full Text] [Related]  

  • 27. Healthcare resource utilization of patients with warm autoimmune hemolytic anemia initiating first line therapy of oral corticosteroids with or without rituximab.
    Murakhovskaya I; Crivera C; Leon A; Alemao E; Anupindi VR; DeKoven M; Divino V; Lin I; Shu C; Ebrahim T
    Ann Hematol; 2024 Apr; 103(4):1139-1147. PubMed ID: 38296903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.
    Berentsen S; Ulvestad E; Langholm R; Beiske K; Hjorth-Hansen H; Ghanima W; Sørbø JH; Tjønnfjord GE
    Haematologica; 2006 Apr; 91(4):460-6. PubMed ID: 16585012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
    Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
    J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
    [No Abstract]   [Full Text] [Related]  

  • 30. Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER).
    Ambrosini A; Estemalik E; Pascual J; Rettiganti M; Stroud C; Day K; Ford J
    J Manag Care Spec Pharm; 2022 Jun; 28(6):645-656. PubMed ID: 35451858
    [No Abstract]   [Full Text] [Related]  

  • 31. Diagnosis and management of autoimmune hemolytic anemia in children.
    Weli M; Ben Hlima A; Belhadj R; Maalej B; Elleuch A; Mekki N; Gargouri L; Kamoun T; Barbouche MR; Mahfoudh A
    Transfus Clin Biol; 2020 Apr; 27(2):61-64. PubMed ID: 32280062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transfusion burden in non-dialysis chronic kidney disease patients with persistent anemia treated in routine clinical practice: a retrospective observational study.
    Fox KM; Yee J; Cong Z; Brooks JM; Petersen J; Lamerato L; Gandra SR
    BMC Nephrol; 2012 Jan; 13():5. PubMed ID: 22273400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sutimlimab in Cold Agglutinin Disease.
    Röth A; Barcellini W; D'Sa S; Miyakawa Y; Broome CM; Michel M; Kuter DJ; Jilma B; Tvedt THA; Fruebis J; Jiang X; Lin S; Reuter C; Morales-Arias J; Hobbs W; Berentsen S
    N Engl J Med; 2021 Apr; 384(14):1323-1334. PubMed ID: 33826820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population.
    Chung H; Crowe CL; Kong SX; Singh R; Farej R; Elliott J; Williamson T; Willey VJ
    J Manag Care Spec Pharm; 2023 Jan; 29(1):80-89. PubMed ID: 36580126
    [No Abstract]   [Full Text] [Related]  

  • 35. Real-world treatment modalities, health care resource utilization, and costs among commercially insured patients with newly diagnosed major depressive disorder in the United States.
    Pizzicato LN; Xie RZ; Yang Y; Grabner M; Chapman RH
    J Manag Care Spec Pharm; 2023 Jun; 29(6):614-625. PubMed ID: 37276037
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.
    Edelman S; Cassarino D; Kayne D; Dex T; Li X; Pasquel FJ
    J Manag Care Spec Pharm; 2022 Sep; 28(9):958-968. PubMed ID: 36001104
    [No Abstract]   [Full Text] [Related]  

  • 37. Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow-up.
    Hansen DL; Möller S; Frederiksen H
    Eur J Haematol; 2022 Jul; 109(1):10-20. PubMed ID: 35276014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States.
    Zhu L; Ferries E; Suthoff E; Namjoshi M; Bera R
    J Manag Care Spec Pharm; 2022 Nov; 28(11-a Suppl):S2-S13. PubMed ID: 36242598
    [No Abstract]   [Full Text] [Related]  

  • 39. Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C.
    Majethia S; Lee IH; Chastek B; Bunner S; Wolf J; Hsiao A; Mozaffari E
    J Manag Care Spec Pharm; 2022 Jan; 28(1):48-57. PubMed ID: 34677088
    [No Abstract]   [Full Text] [Related]  

  • 40. Successful Management of Refractory Autoimmune Hemolytic Anemia with Cold Agglutinin Disease with Splenectomy: A Case Report with Review of Literature.
    Okamoto S; Urade T; Yakushijin K; Kido M; Kuramitsu K; Komatsu S; Gon H; Yamashita H; Shirakawa S; Tsugawa D; Terai S; Yanagimoto H; Toyama H; Fukumoto T
    Kobe J Med Sci; 2023 Jan; 68(1):E30-E34. PubMed ID: 36647084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.